Download PDF
Synlett 2015; 26(12): 1665-1670
DOI: 10.1055/s-0034-1380722
letter
© Georg Thieme Verlag Stuttgart · New York

A Facile Stereoselective Domino Approach for the Construction of Novel Bis(spiropiperidone)–Tetrahydrothiophene Hybrid Heterocycles

Chelliah Bharkavi
,
Sundaravel Vivek Kumar
,
Subbu Perumal*
Further Information

Publication History

Received: 13 January 2015

Accepted after revision: 09 April 2015

Publication Date:
21 May 2015 (online)

    Permissions and Reprints All articles of this category


Abstract

A library of novel bis-spiropiperidone–tetrahydrothiophene hybrid heterocycles have been synthesized via pseudo-three-component domino reaction of (3E,5E)-3,5-bis(arylidene)-1-methyl/benzyl piperidin-4-ones and 1,4-dithiane-2,5-diol in the presence of triethylamine. This transformation presumably proceeds via two annulations each involving the generation of 2-mercaptoacetaldehyde from 1,4-dithiane-2,5-diol–Michael addition–intramolecular aldol sequence which result in the creation of four new bonds in a one-pot operation. The advantages of this protocol are high atom economy, high stereoselectivity, short reaction time, and operational simplicity.

Key words

domino reactions - stereoselectivity - (3E,5E)-3,5-bis(arylidene)-1-methyl/benzylpiperidin-4-ones - 1,4-dithiane-2,5-diol - bis(spiropiperidone)–tetrahydrothiophene hybrids
 

  • References and Notes

  • 1 Both authors contributed equally to this work.
  • 4 Benetti S, De Risi C, Pollini GP, Zanirato V. Chem. Rev. 2012; 112: 2129
    CrossrefPubMedSearch in Google Scholar
  • 7 Yoshikawa M, Murakami T, Shimada H, Matsuda H, Yamahara J, Tanabe G, Muraoka O. Tetrahedron Lett. 1997; 38: 8367
    CrossrefSearch in Google Scholar
  • 8 Tanabe G, Sakano M, Minematsu T, Matusda H, Yoshikawa M, Muraoka O. Tetrahedron 2008; 64: 10080
    CrossrefSearch in Google Scholar
  • 9 Yoshikawa M, Xu FM, Nakamura S, Wang T, Matsuda H, Tanabe G, Muraoka O. Heterocycles 2008; 75: 1397
    CrossrefSearch in Google Scholar
  • 10 Tanabe G, Xie W, Ogawa A, Cao C, Minematsu T, Yoshikawa M, Muraoka O. Bioorg. Med. Chem. Lett. 2009; 19: 2195
    CrossrefSearch in Google Scholar
  • 11 Tanabe G, Yoshikai K, Hatanaka T, Yamamoto M, Shao Y, Minematsu T, Muraoka O, Wang T, Matsuda H, Yoshikawa M. Bioorg. Med. Chem. 2007; 15: 3926
    CrossrefSearch in Google Scholar
  • 12 Nasi R, Patrick BO, Sim L, Rose DR, Pinto BM. J. Org. Chem. 2008; 73: 6172
    CrossrefSearch in Google Scholar
  • 14 Volkmann RA, Kelbaugh PR, Nason DM, Jasys VJ. J. Org. Chem. 1992; 57: 4352
    CrossrefSearch in Google Scholar
  • 15 Haraguchi K, Shimada H, Tanaka H, Hamasaki T, Baba M, Gullen EA, Dutschman GE, Cheng YC. J. Med. Chem. 2008; 51: 1885
    CrossrefSearch in Google Scholar
  • 16 Kato T, Tsuzuki K. JP 147881, 1992 ; Chem. Abstr. 1992, 120, 106750
  • 17 Jeong LS, Lee HW, Jacobson KA, Kim HK, Shin DH, Lee JA, Gao Z.-G, Lu C, Duong HT, Gunaga P, Lee SK, Jin DZ, Chun MW, Moon HR. J. Med. Chem. 2006; 49: 273
    CrossrefSearch in Google Scholar
  • 18 Chorghade MS, Gurjar MK, Palakodety RK, Lalitha SV. S, Sadalapure K, Adhikari SS, Murugaiah AM. S, Rao BV, Talukdar A, Islam A, Hariprasad C, Rao AV. R. WO US 2000001670 A1, 2000 ; Chem. Abstr. 1999, 132, 93203.
  • 19 Tsygoanko VA, Blume YB. Biopolim. Kletka 1997; 13: 484
    Search in Google Scholar
  • 20 Zempleni J, Wijeratne SS, Hassan YI. Biofactors 2009; 35: 36
    CrossrefPubMedSearch in Google Scholar
  • 21 Williams DR, Jass PA, Tse HL. A, Gaston RD. J. Am. Chem. Soc. 1990; 112: 4552
    CrossrefSearch in Google Scholar
  • 25 Reddy PA, Woodward KE, Mcllheran SM, Hsiang BC. H, Latifi TN, Hill MW, Rothman SM, Ferrendelli JA, Covey DF. J. Med. Chem. 1997; 40: 44
    CrossrefPubMedSearch in Google Scholar
  • 26 Olivera A, Moore TW, Hu F, Brown AP, Sun A, Liotta DC, Snyder JP, Yoon Y, Shim H, Marcus AI, Miller AH, Pace TW. W. Int. Immunopharmacol. 2012; 12: 368
    CrossrefSearch in Google Scholar
  • 27 Srinivasan M, Perumal S, Selvaraj S. Chem. Pharm. Bull. 2006; 54: 795
    CrossrefSearch in Google Scholar
  • 28 Pati HN, Das U, Das S, Bandy B, Clercq ED, Balzarini J, Kawase M, Sakagami H, Quail JW, Stables JP, Dimmock JR. Eur. J. Med. Chem. 2009; 44: 54
    CrossrefSearch in Google Scholar
  • 30 Sivakumar S, Ranjith Kumar R, Ashraf Ali M, Choon TS. Eur. J. Med. Chem. 2013; 65: 240
    CrossrefSearch in Google Scholar
  • 31 Duan SW, Li Y, Liu YY, Zou YQ, Shi DQ, Xiao WJ. Chem. Commun. 2012; 48: 5160
    CrossrefSearch in Google Scholar
  • 35 Vivek Kumar S, Prasanna P, Perumal S. Tetrahedron Lett. 2013; 54: 6651
    CrossrefSearch in Google Scholar
  • 37 General Procedure for the Synthesis of 1,8-Bis(aryl)-4,11-dihydroxy-13-methyl/benzyl-2,9-dithia-13-azadispiro[4.1.47.35]tetradecan-6-ones 3a–p A mixture of (3E,5E)-3,5-bis(arylidene)-1-methyl/benzylpiperidin-4-one (1 mmol), 1,4-dithiane-2,5-diol (1 mmol), and Et3N (0.25 equiv) in CH2Cl2 (6 mL) was heated under reflux for 3–4 h. After completion of the reaction (TLC), the solvent was removed and the product was purified by flash column chromatography using a PE–EtOAc mixture (4:1 v/v) as eluent to afford pure compound
  • 38 Characterization Data of Representative Compounds 1,8-Bis(4-fluorophenyl)-4,11-dihydroxy-13-methyl-2,9-dithia-13-azadispiro[4.1.47.35]tetradecan-6-one (3a) White solid; yield 88% (0.38 g); mp 215–216 °C. 1H NMR (300 MHz, CDCl3 + DMSO-d 6): δ = 1.64 (d, 2 H, J = 12.3 Hz), 2.22 (s, 3 H, NCH3), 2.64 (d, 2 H, J = 12.3 Hz), 2.97 (d, 2 H, J = 12.3 Hz), 3.48 (dd, 2 H, J = 12.3, 4.8 Hz), 5.03 (d, 2 H, J = 4.5Hz,), 5.28 (t, 2 H, J = 4.4 Hz), 5.72 (s, 2 H), 6.81–6.87 (m, 4 H, ArH), 7.34–7.44 (m, 4 H, ArH). 13C NMR (75 MHz, CDCl3 + DMSO-d 6): δ = 36.6, 46.5, 50.7, 57.6, 68.2, 79.4, 114.0 (2 J C,F = 20.9 Hz), 131.2 (3 J C,F = 7.8 Hz), 131.4, 161.5 (1 J C,F = 244.9 Hz), 203.5. Anal. Calcd for C24H25F2NO3S2: C, 60.36; H, 5.28; N, 2.93. Found: C, 60.29; H, 5.24; N, 2.99. ESI-MS: m/z calcd: 477.12; found: 478.07 [M+]. 1,8-Bis(4-chlorophenyl)-4,11-dihydroxy-13-methyl-2,9-dithia-13-azadispiro[4.1.47.35]tetradecan-6-one (3b) White solid; yield 85% (0.36 g); mp 225–226 °C. 1H NMR (300 MHz, CDCl3 + DMSO-d 6): δ = 1.62 (d, 2 H, J = 12.0 Hz), 2.22 (s, 3 H, NCH3), 2.64 (d, 2 H, J = 12.0 Hz), 2.95 (d, 2 H, J =12.3 Hz), 3.49 (dd, 2 H, J = 12.2, 4.4 Hz), 5.10 (d, 2 H, J = 3.9 Hz), 5.27 (t, 2 H, J = 5.9 Hz), 5.67 (s, 2 H), 7.13 (d, 4 H, J = 8.4 Hz, ArH), 7.33 (d, 4 H, J = 8.4 Hz, ArH). 13C NMR (75 MHz, CDCl3 + DMSO-d 6): δ = 36.0, 45.8, 50.1, 56.7, 67.6, 78.6, 126.7, 130.4, 131.8, 133.8, 202.8. Anal. Calcd for C24H25Cl2NO3S2: C, 56.47; H, 4.94; N, 2.74. Found: C, 56.58; H, 4.88; N, 2.69. ESI-MS: m/z calcd: 509.07; found: 546.16 [M + Cl]. 1,8-Bis(4-bromophenyl)-4,11-dihydroxy-13-methyl-2,9-dithia-13-azadispiro[4.1.47.35]tetradecan-6-one (3c) White solid; yield 83% (0.33 g); mp 227–228 °C. 1H NMR (300 MHz, CDCl3 + DMSO-d 6): δ = 1.64 (d, 2 H, J = 12.0 Hz), 2.22 (s, 3 H, NCH3), 2.63 (d, 2 H, J = 12.0 Hz,), 2.99 (d, 2 H, J = 12.3 Hz), 3.48 (dd, 2 H, J = 12.3, 4.8 Hz), 4.99 (d, 2 H, J = 4.5 Hz), 5.26 (t, 2 H, J = 4.4 Hz), 5.69 (s, 2 H), 7.24–7.30 (m, 6 H, ArH), 7.42–7.43(m, 2 H, ArH). 13C NMR (75 MHz, CDCl3 + DMSO-d 6): δ = 36.5, 46.2, 50.7, 57.2, 68.0, 79.2, 120.7, 130.2, 131.2, 134.7, 203.3. Anal. Calcd for C24H25Br2NO3S2: C, 48.09; H, 4.20; N, 2.34. Found: C, 48.12; H, 4.28; N, 2.30. ESI-MS: m/z calcd: 598.96; found: 634.16 [M + Cl]
  • 39 General Procedure for the Synthesis of 3-[(E)-4-arylidene]-1-methyl-5-[(E)-4-arylidene]piperidin-4-ones 1q,r The synthesis of (E)-1-methyl-3-(arylidene)piperidin-4-ones was performed from our earlier reported procedure.42 Unsymmetrically substituted 3-[(E)-4-arylidene]-1-methyl-5-[(E)-4-arylidene]piperidin-4-one were synthesized from previous reports43 with simple modification. A mixture of (E)-1-methyl-3-(arylidene)piperidin-4-ones (1 mmol) and Ba(OH)2·8H2O (1 mmol) in EtOH was reacted under stirring conditions for 5 min. Then aromatic aldehyde (1 mmol) was dissolved in EtOH and was added dropwise. After completion of the addition the resulting mixture was stirred for further 3 h. After completion of the reaction with evident TLC, the precipitated solid was filtered and washed with cold EtOH that afforded pure 1q and 1r.
  • 40 Characterization Data of Unsymmetrically Substituted Di­arylidines 3-[(E)-benzylidene]-1-methyl-5-[(E)-4-methylbenzylid­ene]piperidin-4-one (1q) Yellow solid; yield 88% (0.39 g); mp 185–186 °C. 1H NMR (300 MHz, CDCl3): δ = 2.40 (s, 3 H, NCH3), 2.48 (s, 3 H), 3.79 (s, 4 H), 7.22–7.32 (m, 7 H, ArH), 7.41–7.43 (m, 2 H, ArH), 7.81(s, 2 H, ArH). 13C NMR (75 MHz, CDCl3): δ = 21.4, 45.8, 57.1, 129.3, 130.5, 132.4, 132.5, 136.4, 139.3, 186.9. Anal. Calcd for C21H21NO: C, 83.13; H, 6.98; N, 4.62. Found: C, 83.05; H, 6.86; N, 4.69. 1-Methyl-3-[(E)-4-methylbenzylidene]-5-[(E)-4-nitrobenz­ylidene]piperidin-4-one (1r) Yellow solid; yield 90% (0.46 g); mp 164–165 °C. 1H NMR (300 MHz, CDCl3): δ = 2.40 (s, 3 H, NCH3), 2.48 (s, 3 H), 3.73 (s, 2 H), 3.79 (s, 2 H), 7.25, (d, 2 H, J = 8.4 Hz, ArH), 7.32 (d, 2 H, J = 8.1 Hz, ArH), 7.53 (d, 2 H, J = 8.7 Hz, ArH), 7.79 (s, 1 H), 7.81 (s, 1 H), 8.28 (d, 2 H, J = 8.7 Hz, ArH). 13C NMR (75 MHz, CDCl3): δ = 21.3, 45.7, 56.6, 57.0, 123.5, 129.3, 130.5, 130.6, 131.7, 131.9, 132.7, 136.2, 137.2, 139.7, 141.6, 147.2, 186.1. Anal. Calcd for C21H20N2O3: C, 72.40; H, 5.79; N, 8.04. Found: C, 72.46; H, 5.71; N, 8.16. ESI-MS: m/z calcd: 348.15; found: 349.18 [M+]
  • 41 Crystallographic data (excluding structure factors) for compound 3b in this letter have been deposited with the Cambridge Crystallographic Data Centre as supplementary publication number CCDC 999878. Copies of the data can be obtained, free of charge, on application to CCDC, 12 Union Road, Cambridge CB2 1EZ, UK [fax: +44 (0)1223-336033 or e-mail: deposit@ccdc.cam.ac.uk].
  • 42 Suresh Kumar R, Perumal S, Kagan HB, Guillot R. Tetrahedron Asymmetry 2007; 18: 170
    CrossrefSearch in Google Scholar
  • 43 Mai A, Cheng D, Bedford MT, Valente S, Nebbioso A, Perrone A, Brosch G, Sbardella G, De Bellis F, Miceli M, Altucci L. J. Med. Chem. 2008; 51: 2279
    CrossrefSearch in Google Scholar